Cynata Therapeutics Limited (CYYNF) AI Stock Analysis

Cynata Therapeutics Limited

(Other OTC:CYYNF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Debt-free balance sheetZero debt reduces interest obligations and refinancing exposure, giving the company more flexibility than a similarly loss-making business with leverage. This provides some capacity to direct future funding toward clinical development, although it does not remove the need for external capital.

Negative Factors

Persistent losses and weak operating performancePersistent losses that are large relative to revenue show that the company has not yet converted its development platform into sustainable operating earnings. Continued negative margins can consume capital for several quarters and make future progress dependent on successful clinical and commercial execution.

Cynata Therapeutics Limited (CYYNF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $1.75M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.3
Beta (1Y): -1.37
Revenue Growth: ―
EPS Growth: 7.81%
Country: US
Employees: 0
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Cynata Therapeutics Limited Business Overview & Revenue Model

Company Description

Headquartered in Cremorne, Australia, Cynata Therapeutics Limited, established in 2003 and formerly known as Eco Quest Limited until its 2013 rebranding, specializes in the development and commercialization of its proprietary Cymerus mesenchymal stem...

Cynata Therapeutics Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CYYNF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AU:MSB	64Neutral	AUD 2.94B	-35.83	-10.06%	―	555.67%	49.08%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AU:OCC	50Neutral	AUD 149.82M	-10.38	-36.83%	―	51.07%	-47.63%
AU:CMB	41Neutral	AUD 11.77M	-1.59	-247.44%	―	-4.24%	33.39%
AU:1AI	40Underperform	AUD 20.28M	-5.71	-132.20%	―	―	-200.00%
AU:TRP	32Underperform	AUD 5.06M	-1.07	-52.04%	―	32.22%	-26.53%

* Healthcare Sector Average

Performance Comparison

CYYNF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CYYNF	Cynata Therapeutics Limited	0.22	0.10	88.14%
AU:1AI	Living Cell Technologies Ltd.	0.01	0.00	0.00%
AU:MSB	Mesoblast Limited	2.26	-0.22	-8.87%
AU:OCC	Orthocell Ltd	0.55	-0.64	-53.78%
AU:TRP	Tissue Repair Ltd	0.10	-0.24	-71.21%
AU:CMB	Regeneus Ltd.	0.40	-0.09	-19.19%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Cynata Therapeutics Limited AI Stock Analysis